nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT2B7—Epirubicin—testicular cancer	0.168	0.259	CbGbCtD
Dapagliflozin—CYP2A6—Ifosfamide—testicular cancer	0.141	0.216	CbGbCtD
Dapagliflozin—CYP2C9—Ifosfamide—testicular cancer	0.0485	0.0744	CbGbCtD
Dapagliflozin—ABCB1—Dactinomycin—testicular cancer	0.0399	0.0612	CbGbCtD
Dapagliflozin—CYP3A4—Ifosfamide—testicular cancer	0.0282	0.0433	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—testicular cancer	0.0257	0.0395	CbGbCtD
Dapagliflozin—ABCB1—Vinblastine—testicular cancer	0.025	0.0383	CbGbCtD
Dapagliflozin—CYP2C9—Cisplatin—testicular cancer	0.0236	0.0362	CbGbCtD
Dapagliflozin—CYP2D6—Vinblastine—testicular cancer	0.0235	0.0361	CbGbCtD
Dapagliflozin—ABCB1—Cisplatin—testicular cancer	0.0229	0.0351	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—testicular cancer	0.0225	0.0345	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—testicular cancer	0.0153	0.0235	CbGbCtD
Dapagliflozin—CYP3A4—Vinblastine—testicular cancer	0.015	0.023	CbGbCtD
Dapagliflozin—SLC5A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0149	0.117	CbGpPWpGaD
Dapagliflozin—ABCB1—Methotrexate—testicular cancer	0.0149	0.0228	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—testicular cancer	0.0145	0.0222	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—testicular cancer	0.0135	0.0207	CbGbCtD
Dapagliflozin—SLC5A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0109	0.0856	CbGpPWpGaD
Dapagliflozin—SLC5A11—NRF2 pathway—SLC2A6—testicular cancer	0.0107	0.0846	CbGpPWpGaD
Dapagliflozin—CYP3A4—Doxorubicin—testicular cancer	0.00919	0.0141	CbGbCtD
Dapagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00822	0.0649	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00822	0.0649	CbGpPWpGaD
Dapagliflozin—SLC5A4—NRF2 pathway—SLC2A6—testicular cancer	0.00782	0.0617	CbGpPWpGaD
Dapagliflozin—SLC5A11—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00676	0.0533	CbGpPWpGaD
Dapagliflozin—SLC5A2—NRF2 pathway—SLC2A6—testicular cancer	0.00593	0.0468	CbGpPWpGaD
Dapagliflozin—SLC5A1—NRF2 pathway—SLC2A6—testicular cancer	0.00593	0.0468	CbGpPWpGaD
Dapagliflozin—SLC5A4—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00493	0.0389	CbGpPWpGaD
Dapagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00374	0.0295	CbGpPWpGaD
Dapagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00374	0.0295	CbGpPWpGaD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00343	0.0271	CbGpPWpGaD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00251	0.0198	CbGpPWpGaD
Dapagliflozin—UGT2B4—Phase II conjugation—HPGDS—testicular cancer	0.00249	0.0197	CbGpPWpGaD
Dapagliflozin—UGT2B7—NRF2 pathway—SLC2A6—testicular cancer	0.00208	0.0165	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.0019	0.015	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.0019	0.015	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—SLC2A6—testicular cancer	0.00169	0.0134	CbGpPWpGaD
Dapagliflozin—UGT2B4—Biological oxidations—HPGDS—testicular cancer	0.00146	0.0115	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	0.00131	0.0103	CbGpPWpGaD
Dapagliflozin—UGT2B7—Phase II conjugation—HPGDS—testicular cancer	0.00113	0.00895	CbGpPWpGaD
Dapagliflozin—UGT1A9—Phase II conjugation—HPGDS—testicular cancer	0.000922	0.00728	CbGpPWpGaD
Dapagliflozin—Acute coronary syndrome—Bleomycin—testicular cancer	0.000906	0.00409	CcSEcCtD
Dapagliflozin—Myocardial infarction—Bleomycin—testicular cancer	0.000901	0.00406	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Cisplatin—testicular cancer	0.000897	0.00405	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00089	0.00702	CbGpPWpGaD
Dapagliflozin—Hyponatraemia—Cisplatin—testicular cancer	0.000883	0.00398	CcSEcCtD
Dapagliflozin—Lung disorder—Epirubicin—testicular cancer	0.000879	0.00396	CcSEcCtD
Dapagliflozin—Fungal infection—Methotrexate—testicular cancer	0.000861	0.00388	CcSEcCtD
Dapagliflozin—Angina pectoris—Ifosfamide—testicular cancer	0.000859	0.00387	CcSEcCtD
Dapagliflozin—Angioedema—Chlorambucil—testicular cancer	0.000848	0.00383	CcSEcCtD
Dapagliflozin—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000832	0.00657	CbGpPWpGaD
Dapagliflozin—Dysuria—Ifosfamide—testicular cancer	0.000824	0.00372	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Cisplatin—testicular cancer	0.000824	0.00371	CcSEcCtD
Dapagliflozin—Dehydration—Cisplatin—testicular cancer	0.000818	0.00369	CcSEcCtD
Dapagliflozin—Pollakiuria—Ifosfamide—testicular cancer	0.000814	0.00367	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—testicular cancer	0.000813	0.00367	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—testicular cancer	0.000805	0.00363	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Cisplatin—testicular cancer	0.000803	0.00362	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Cisplatin—testicular cancer	0.000786	0.00355	CcSEcCtD
Dapagliflozin—Infestation—Ifosfamide—testicular cancer	0.000786	0.00354	CcSEcCtD
Dapagliflozin—Infestation NOS—Ifosfamide—testicular cancer	0.000786	0.00354	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Ifosfamide—testicular cancer	0.000775	0.00349	CcSEcCtD
Dapagliflozin—Renal failure—Ifosfamide—testicular cancer	0.000773	0.00348	CcSEcCtD
Dapagliflozin—Myocardial infarction—Ifosfamide—testicular cancer	0.00077	0.00347	CcSEcCtD
Dapagliflozin—Extravasation—Methotrexate—testicular cancer	0.000762	0.00343	CcSEcCtD
Dapagliflozin—Infection—Chlorambucil—testicular cancer	0.000753	0.00339	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—testicular cancer	0.000745	0.00336	CcSEcCtD
Dapagliflozin—Hypertension—Vinblastine—testicular cancer	0.000735	0.00331	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Epirubicin—testicular cancer	0.000728	0.00328	CcSEcCtD
Dapagliflozin—Discomfort—Vinblastine—testicular cancer	0.000716	0.00323	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—testicular cancer	0.000713	0.00321	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Ifosfamide—testicular cancer	0.000697	0.00314	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Ifosfamide—testicular cancer	0.000693	0.00313	CcSEcCtD
Dapagliflozin—Urethral disorder—Ifosfamide—testicular cancer	0.000692	0.00312	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—testicular cancer	0.000674	0.00304	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—testicular cancer	0.00067	0.00302	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Cisplatin—testicular cancer	0.000668	0.00301	CcSEcCtD
Dapagliflozin—Renal failure—Cisplatin—testicular cancer	0.000666	0.003	CcSEcCtD
Dapagliflozin—Myocardial infarction—Cisplatin—testicular cancer	0.000664	0.00299	CcSEcCtD
Dapagliflozin—UGT2B7—Biological oxidations—HPGDS—testicular cancer	0.000664	0.00524	CbGpPWpGaD
Dapagliflozin—Extravasation—Doxorubicin—testicular cancer	0.00066	0.00297	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000654	0.00295	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—testicular cancer	0.000627	0.00283	CcSEcCtD
Dapagliflozin—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000621	0.0049	CbGpPWpGaD
Dapagliflozin—Infestation—Etoposide—testicular cancer	0.000621	0.0028	CcSEcCtD
Dapagliflozin—Infestation NOS—Etoposide—testicular cancer	0.000621	0.0028	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—testicular cancer	0.00062	0.0028	CcSEcCtD
Dapagliflozin—Malnutrition—Ifosfamide—testicular cancer	0.000614	0.00277	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Etoposide—testicular cancer	0.000612	0.00276	CcSEcCtD
Dapagliflozin—Renal failure—Etoposide—testicular cancer	0.00061	0.00275	CcSEcCtD
Dapagliflozin—Myocardial infarction—Etoposide—testicular cancer	0.000608	0.00274	CcSEcCtD
Dapagliflozin—Discomfort—Bleomycin—testicular cancer	0.000604	0.00273	CcSEcCtD
Dapagliflozin—Urticaria—Chlorambucil—testicular cancer	0.000602	0.00271	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—testicular cancer	0.000601	0.00271	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—testicular cancer	0.000601	0.00271	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Cisplatin—testicular cancer	0.000601	0.00271	CcSEcCtD
Dapagliflozin—Body temperature increased—Chlorambucil—testicular cancer	0.000599	0.0027	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Cisplatin—testicular cancer	0.000598	0.0027	CcSEcCtD
Dapagliflozin—Urethral disorder—Cisplatin—testicular cancer	0.000596	0.00269	CcSEcCtD
Dapagliflozin—Constipation—Vinblastine—testicular cancer	0.000594	0.00268	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—testicular cancer	0.000587	0.00265	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—testicular cancer	0.000587	0.00265	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Bleomycin—testicular cancer	0.000586	0.00264	CcSEcCtD
Dapagliflozin—Oedema—Bleomycin—testicular cancer	0.000586	0.00264	CcSEcCtD
Dapagliflozin—Infection—Bleomycin—testicular cancer	0.000583	0.00263	CcSEcCtD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000567	0.00448	CbGpPWpGaD
Dapagliflozin—Discomfort—Dactinomycin—testicular cancer	0.000564	0.00254	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—testicular cancer	0.000562	0.00254	CcSEcCtD
Dapagliflozin—Angioedema—Ifosfamide—testicular cancer	0.000561	0.00253	CcSEcCtD
Dapagliflozin—Hypersensitivity—Chlorambucil—testicular cancer	0.000558	0.00252	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—testicular cancer	0.000555	0.0025	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Etoposide—testicular cancer	0.00055	0.00248	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—testicular cancer	0.000549	0.00248	CcSEcCtD
Dapagliflozin—Hypotension—Bleomycin—testicular cancer	0.000548	0.00247	CcSEcCtD
Dapagliflozin—Oedema—Dactinomycin—testicular cancer	0.000547	0.00247	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—testicular cancer	0.000546	0.00246	CcSEcCtD
Dapagliflozin—Infection—Dactinomycin—testicular cancer	0.000543	0.00245	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—testicular cancer	0.000543	0.00245	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—testicular cancer	0.000543	0.00245	CcSEcCtD
Dapagliflozin—UGT1A9—Biological oxidations—HPGDS—testicular cancer	0.000539	0.00426	CbGpPWpGaD
Dapagliflozin—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000531	0.00419	CbGpPWpGaD
Dapagliflozin—Hypertension—Ifosfamide—testicular cancer	0.00053	0.00239	CcSEcCtD
Dapagliflozin—Malnutrition—Cisplatin—testicular cancer	0.000529	0.00239	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—testicular cancer	0.000524	0.00236	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—testicular cancer	0.00052	0.00235	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000519	0.00234	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—testicular cancer	0.000519	0.00234	CcSEcCtD
Dapagliflozin—Discomfort—Ifosfamide—testicular cancer	0.000517	0.00233	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vinblastine—testicular cancer	0.000512	0.00231	CcSEcCtD
Dapagliflozin—Oedema—Ifosfamide—testicular cancer	0.000501	0.00226	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Ifosfamide—testicular cancer	0.000501	0.00226	CcSEcCtD
Dapagliflozin—Infection—Ifosfamide—testicular cancer	0.000498	0.00225	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—testicular cancer	0.000492	0.00222	CcSEcCtD
Dapagliflozin—Skin disorder—Ifosfamide—testicular cancer	0.000487	0.0022	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—testicular cancer	0.000485	0.00219	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Ifosfamide—testicular cancer	0.000485	0.00218	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—testicular cancer	0.00048	0.00217	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—testicular cancer	0.000469	0.00212	CcSEcCtD
Dapagliflozin—Hypotension—Ifosfamide—testicular cancer	0.000468	0.00211	CcSEcCtD
Dapagliflozin—Urticaria—Bleomycin—testicular cancer	0.000466	0.0021	CcSEcCtD
Dapagliflozin—Body temperature increased—Bleomycin—testicular cancer	0.000464	0.00209	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—testicular cancer	0.000463	0.00209	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—testicular cancer	0.000461	0.00208	CcSEcCtD
Dapagliflozin—Dizziness—Vinblastine—testicular cancer	0.000459	0.00207	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—testicular cancer	0.000453	0.00204	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—testicular cancer	0.000451	0.00204	CcSEcCtD
Dapagliflozin—Nausea—Chlorambucil—testicular cancer	0.00045	0.00203	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000448	0.00202	CcSEcCtD
Dapagliflozin—Discomfort—Cisplatin—testicular cancer	0.000445	0.00201	CcSEcCtD
Dapagliflozin—Headache—Vinblastine—testicular cancer	0.000435	0.00196	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000433	0.00195	CcSEcCtD
Dapagliflozin—Body temperature increased—Dactinomycin—testicular cancer	0.000432	0.00195	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Cisplatin—testicular cancer	0.000432	0.00195	CcSEcCtD
Dapagliflozin—Oedema—Cisplatin—testicular cancer	0.000432	0.00195	CcSEcCtD
Dapagliflozin—Hypersensitivity—Bleomycin—testicular cancer	0.000432	0.00195	CcSEcCtD
Dapagliflozin—Infection—Cisplatin—testicular cancer	0.000429	0.00194	CcSEcCtD
Dapagliflozin—Constipation—Ifosfamide—testicular cancer	0.000429	0.00193	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—testicular cancer	0.000428	0.00193	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000426	0.00192	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—HPGDS—testicular cancer	0.000426	0.00336	CbGpPWpGaD
Dapagliflozin—Blood creatinine increased—Epirubicin—testicular cancer	0.000423	0.00191	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—testicular cancer	0.00042	0.00189	CcSEcCtD
Dapagliflozin—Skin disorder—Cisplatin—testicular cancer	0.00042	0.00189	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—testicular cancer	0.000419	0.00189	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—testicular cancer	0.000419	0.00189	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—testicular cancer	0.000418	0.00188	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Cisplatin—testicular cancer	0.000418	0.00188	CcSEcCtD
Dapagliflozin—CYP2A6—Biological oxidations—HPGDS—testicular cancer	0.000416	0.00328	CbGpPWpGaD
Dapagliflozin—Nausea—Vinblastine—testicular cancer	0.000412	0.00186	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—testicular cancer	0.000412	0.00186	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00041	0.00185	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—testicular cancer	0.000408	0.00184	CcSEcCtD
Dapagliflozin—Hypotension—Cisplatin—testicular cancer	0.000404	0.00182	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—testicular cancer	0.000404	0.00182	CcSEcCtD
Dapagliflozin—Hypersensitivity—Dactinomycin—testicular cancer	0.000403	0.00182	CcSEcCtD
Dapagliflozin—Urticaria—Ifosfamide—testicular cancer	0.000398	0.0018	CcSEcCtD
Dapagliflozin—Body temperature increased—Ifosfamide—testicular cancer	0.000396	0.00179	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—testicular cancer	0.000396	0.00179	CcSEcCtD
Dapagliflozin—Infection—Etoposide—testicular cancer	0.000393	0.00177	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—testicular cancer	0.000391	0.00176	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—testicular cancer	0.00039	0.00176	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—testicular cancer	0.00039	0.00176	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—testicular cancer	0.000388	0.00175	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—testicular cancer	0.000385	0.00173	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—testicular cancer	0.000383	0.00173	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—testicular cancer	0.000382	0.00172	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—testicular cancer	0.00038	0.00171	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—testicular cancer	0.000374	0.00168	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000373	0.00168	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—testicular cancer	0.000372	0.00168	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—testicular cancer	0.000372	0.00168	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—H2AFZ—testicular cancer	0.000372	0.00293	CbGpPWpGaD
Dapagliflozin—Hypotension—Etoposide—testicular cancer	0.00037	0.00167	CcSEcCtD
Dapagliflozin—Rash—Bleomycin—testicular cancer	0.00037	0.00167	CcSEcCtD
Dapagliflozin—Dermatitis—Bleomycin—testicular cancer	0.000369	0.00167	CcSEcCtD
Dapagliflozin—Hypersensitivity—Ifosfamide—testicular cancer	0.000369	0.00167	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—testicular cancer	0.000365	0.00165	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—testicular cancer	0.000365	0.00165	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—testicular cancer	0.000361	0.00163	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—testicular cancer	0.00036	0.00163	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—testicular cancer	0.000352	0.00159	CcSEcCtD
Dapagliflozin—Nausea—Bleomycin—testicular cancer	0.000348	0.00157	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—testicular cancer	0.000348	0.00157	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—testicular cancer	0.000348	0.00157	CcSEcCtD
Dapagliflozin—Rash—Dactinomycin—testicular cancer	0.000345	0.00156	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—testicular cancer	0.000342	0.00154	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—KITLG—testicular cancer	0.000342	0.0027	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Etoposide—testicular cancer	0.000342	0.00154	CcSEcCtD
Dapagliflozin—Body temperature increased—Cisplatin—testicular cancer	0.000342	0.00154	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—testicular cancer	0.000339	0.00153	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—testicular cancer	0.000338	0.00153	CcSEcCtD
Dapagliflozin—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000338	0.00266	CbGpPWpGaD
Dapagliflozin—Dysuria—Doxorubicin—testicular cancer	0.000338	0.00152	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—testicular cancer	0.000334	0.0015	CcSEcCtD
Dapagliflozin—Dizziness—Ifosfamide—testicular cancer	0.000331	0.00149	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—testicular cancer	0.00033	0.00149	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—testicular cancer	0.000327	0.00148	CcSEcCtD
Dapagliflozin—Nausea—Dactinomycin—testicular cancer	0.000325	0.00147	CcSEcCtD
Dapagliflozin—SLC5A2—Metabolism—HPGDS—testicular cancer	0.000323	0.00255	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—HPGDS—testicular cancer	0.000323	0.00255	CbGpPWpGaD
Dapagliflozin—Infestation—Doxorubicin—testicular cancer	0.000322	0.00145	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—testicular cancer	0.000322	0.00145	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cisplatin—testicular cancer	0.000318	0.00144	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—testicular cancer	0.000316	0.00143	CcSEcCtD
Dapagliflozin—Rash—Ifosfamide—testicular cancer	0.000316	0.00143	CcSEcCtD
Dapagliflozin—Dermatitis—Ifosfamide—testicular cancer	0.000316	0.00142	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—testicular cancer	0.000314	0.00142	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—testicular cancer	0.000313	0.00141	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—testicular cancer	0.000313	0.00141	CcSEcCtD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.00031	0.00245	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—HPGDS—testicular cancer	0.00031	0.00244	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—STK11—testicular cancer	0.000309	0.00244	CbGpPWpGaD
Dapagliflozin—Urinary tract disorder—Epirubicin—testicular cancer	0.000308	0.00139	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—testicular cancer	0.000307	0.00138	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—testicular cancer	0.000306	0.00138	CcSEcCtD
Dapagliflozin—Nausea—Ifosfamide—testicular cancer	0.000298	0.00134	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etoposide—testicular cancer	0.000292	0.00132	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—testicular cancer	0.000291	0.00131	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—testicular cancer	0.000285	0.00129	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—testicular cancer	0.000284	0.00128	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—testicular cancer	0.000283	0.00128	CcSEcCtD
Dapagliflozin—SLC5A1—Disease—H2AFZ—testicular cancer	0.000282	0.00222	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—H2AFZ—testicular cancer	0.000282	0.00222	CbGpPWpGaD
Dapagliflozin—Back pain—Methotrexate—testicular cancer	0.000281	0.00127	CcSEcCtD
Dapagliflozin—Rash—Cisplatin—testicular cancer	0.000272	0.00123	CcSEcCtD
Dapagliflozin—Dermatitis—Cisplatin—testicular cancer	0.000272	0.00123	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—testicular cancer	0.000272	0.00123	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—testicular cancer	0.000263	0.00119	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—testicular cancer	0.000262	0.00118	CcSEcCtD
Dapagliflozin—SLC5A2—Disease—KITLG—testicular cancer	0.000259	0.00204	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—KITLG—testicular cancer	0.000259	0.00204	CbGpPWpGaD
Dapagliflozin—Nausea—Cisplatin—testicular cancer	0.000257	0.00116	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—FGFR3—testicular cancer	0.000254	0.00201	CbGpPWpGaD
Dapagliflozin—Malnutrition—Doxorubicin—testicular cancer	0.000252	0.00113	CcSEcCtD
Dapagliflozin—Rash—Etoposide—testicular cancer	0.00025	0.00113	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—testicular cancer	0.000249	0.00112	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—HPGDS—testicular cancer	0.000249	0.00197	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000249	0.00196	CbGpPWpGaD
Dapagliflozin—Headache—Etoposide—testicular cancer	0.000248	0.00112	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000246	0.00111	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—testicular cancer	0.000244	0.0011	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—testicular cancer	0.000243	0.0011	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—testicular cancer	0.000237	0.00107	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—testicular cancer	0.000236	0.00106	CcSEcCtD
Dapagliflozin—Nausea—Etoposide—testicular cancer	0.000235	0.00106	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—testicular cancer	0.000235	0.00106	CcSEcCtD
Dapagliflozin—SLC5A1—Metabolism—STK11—testicular cancer	0.000235	0.00185	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—STK11—testicular cancer	0.000235	0.00185	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—KIT—testicular cancer	0.000233	0.00184	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000233	0.00184	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—HPGDS—testicular cancer	0.000231	0.00182	CbGpPWpGaD
Dapagliflozin—Skin disorder—Methotrexate—testicular cancer	0.00023	0.00104	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00023	0.00104	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—testicular cancer	0.000229	0.00103	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—testicular cancer	0.000229	0.00103	CcSEcCtD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000228	0.0018	CbGpPWpGaD
Dapagliflozin—Oedema—Epirubicin—testicular cancer	0.000222	0.001	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—testicular cancer	0.000222	0.001	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—testicular cancer	0.000222	0.000999	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—testicular cancer	0.00022	0.000994	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—testicular cancer	0.000217	0.000979	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—testicular cancer	0.000216	0.000972	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—testicular cancer	0.000215	0.000967	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000213	0.000959	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—testicular cancer	0.000212	0.000954	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—testicular cancer	0.000207	0.000935	CcSEcCtD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000207	0.00163	CbGpPWpGaD
Dapagliflozin—Anaphylactic shock—Doxorubicin—testicular cancer	0.000205	0.000926	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—testicular cancer	0.000205	0.000926	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000205	0.000923	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—testicular cancer	0.000204	0.00092	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—testicular cancer	0.000199	0.000899	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—testicular cancer	0.000198	0.000895	CcSEcCtD
Dapagliflozin—CYP1A2—Biological oxidations—HPGDS—testicular cancer	0.000198	0.00156	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—FGFR3—testicular cancer	0.000193	0.00152	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—FGFR3—testicular cancer	0.000193	0.00152	CbGpPWpGaD
Dapagliflozin—Hypotension—Doxorubicin—testicular cancer	0.000192	0.000865	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000192	0.000864	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—testicular cancer	0.00019	0.000856	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—testicular cancer	0.000188	0.000849	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—testicular cancer	0.000187	0.000845	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—STK11—testicular cancer	0.000181	0.00143	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000177	0.000799	CcSEcCtD
Dapagliflozin—SLC5A1—Disease—KIT—testicular cancer	0.000177	0.0014	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—KIT—testicular cancer	0.000177	0.0014	CbGpPWpGaD
Dapagliflozin—Urticaria—Epirubicin—testicular cancer	0.000176	0.000795	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—testicular cancer	0.000176	0.000792	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—testicular cancer	0.000175	0.000791	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—testicular cancer	0.000175	0.000788	CcSEcCtD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000165	0.0013	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Epirubicin—testicular cancer	0.000163	0.000737	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—testicular cancer	0.000163	0.000736	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—testicular cancer	0.000162	0.000732	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—testicular cancer	0.000157	0.000707	CcSEcCtD
Dapagliflozin—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000152	0.0012	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Doxorubicin—testicular cancer	0.000151	0.000682	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—testicular cancer	0.00015	0.000674	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—testicular cancer	0.000149	0.000674	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—testicular cancer	0.000149	0.00067	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—testicular cancer	0.000147	0.000662	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—testicular cancer	0.000141	0.000635	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—testicular cancer	0.00014	0.000631	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—testicular cancer	0.00014	0.00063	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—testicular cancer	0.000139	0.000627	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—testicular cancer	0.000136	0.000612	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—testicular cancer	0.000132	0.000594	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—testicular cancer	0.000129	0.000584	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—testicular cancer	0.000129	0.000583	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—testicular cancer	0.000129	0.00058	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—testicular cancer	0.000122	0.00055	CcSEcCtD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000119	0.000939	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—HPGDS—testicular cancer	0.000114	0.000896	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—HPGDS—testicular cancer	9.22e-05	0.000728	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.88e-05	0.0007	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—STK11—testicular cancer	8.25e-05	0.000651	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.59e-05	0.000599	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HPGDS—testicular cancer	7.11e-05	0.000561	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—STK11—testicular cancer	6.7e-05	0.000529	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HPGDS—testicular cancer	5.3e-05	0.000418	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—STK11—testicular cancer	5.17e-05	0.000408	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HPGDS—testicular cancer	4.23e-05	0.000334	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HPGDS—testicular cancer	3.99e-05	0.000315	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HPGDS—testicular cancer	3.95e-05	0.000312	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—STK11—testicular cancer	3.85e-05	0.000304	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HPGDS—testicular cancer	3.38e-05	0.000267	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—STK11—testicular cancer	3.07e-05	0.000243	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—STK11—testicular cancer	2.9e-05	0.000229	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—STK11—testicular cancer	2.87e-05	0.000227	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HPGDS—testicular cancer	2.61e-05	0.000206	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—STK11—testicular cancer	2.45e-05	0.000194	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—STK11—testicular cancer	1.89e-05	0.000149	CbGpPWpGaD
